Special Article
Shattuck Lecture
Diversity of the Immune Repertoire and Immunoregulation
N Engl J Med 2003; 348:1017-1026March 13, 2003
- Article
Since the midpoint of the 20th century, medical advances in economically developed countries have exceeded all expectations. In 1950, the year I entered medical school, the average life expectancy in the United States was 68 years. By 2000, it was 77 years (80 years for women).1 In 1957, when I began my fellowship in hematology, there was no combination chemotherapy, the choice of antibiotics was limited, computed tomography and magnetic resonance imaging did not exist, and most neoplasms were incurable. And in 1958, the year I began my research on immunosuppressive drugs, the role of the lymphocyte was unclear, and successful organ and bone marrow transplantation lay in the future.
This is not a comprehensive review, but rather a personal reflection on some aspects of immunology with clinical relevance. My main point is that the immune system's enormous repertoire of antigen receptors allows reactivity not only against pathogens, but also against autoantigens. This potential disadvantage is countered, however, by potent regulatory mechanisms that reduce the risk of harm. Research on these mechanisms has changed clinical practice by uncovering new ways of controlling autoimmune diseases and preventing graft rejection.
Clonal Selection
In 1900, Paul Ehrlich, one of the leading immunologists of the time, published “On Immunity with Special Reference to Cell Life,” a detailed account of his receptor theory of the immune response.2 To convey his ideas, Ehrlich broke with tradition and taboo by showing diagrams of hypothetical molecules — at the time, there was no physical evidence that antibodies existed, and diagrams were regarded as vulgar popularizations of complex matters.3 Despite fierce opposition, especially to the diagrams, Ehrlich's paper became one of the most highly cited publications in the literature on immunology because it introduced a radically new way of thinking about the immune system.
The essence of Ehrlich's idea, in modern terms, is that antigens bind to preexisting cell-surface receptors (surface immunoglobulins) and thereby stimulate the cell to produce more receptors and to secrete them, in the form of antibodies, into the extracellular fluid.4 Ehrlich's concept implied that the immune system generates an array of unique receptors before it has any contact with antigens. Like a falling star, this brilliant insight soon vanished, because Ehrlich's contemporaries could not believe that the body has foreknowledge of any compound a chemist could synthesize. Today, Ehrlich's idea is a principal feature of the clonal-selection theory, the basis of modern immunology.5-8
The clonal-selection theory asserts that B cells have a proliferative advantage during an immune response if their receptors have a high affinity for the immunogen. When it was introduced in the mid-1950s, the theory shifted the orientation of immunology from chemistry to cells, thereby sparking a revolution in our understanding of how the immune system works. Its implications for clinical medicine were immediately apparent, because it rooted the immune system in clones of lymphocytes, thereby identifying the real targets for the harnessing of unwanted immunity.
The Generation of Diversity
Recombination of Variable-Region Genes
The antigen receptors displayed by B cells and T cells each have two components: B cells have heavy and light chains, and most T cells have α and β chains (Figure 1Figure 1
The Generation of Antibody Diversity.). The human body contains approximately 1010 lymphocytes, each with a unique combination of gene segments that specify the variable region, the part of the receptor that binds antigen.11 Figure 1 shows how, in the developing B cell, random recombination of heavy-chain genes (VH, D, and JH ) and light-chain genes (V κ and J κ) culminates in VH DJH (heavy chain) and V κJ κ (light chain) coding units.12 The random shuffling of numerous variable-region genes10 deals each B cell a distinctive receptor. A similar principle underlies the formation of the T-cell receptor. Adding to variable-region diversity is the insertion of nucleotides (adenine, guanine, cytosine, and thymidine) in a random order into the joints between the DJH and VH D segments13 (Figure 1).Complementarity-Determining Regions
Over 30 years ago, Kabat and Wu identified subregions within the variable region called complementarity-determining regions.14 Virtually all the variation in populations of antibodies is due to these regions. They form the pocket in the variable region that binds to an antigen with a complementary shape — hence their name. In newly formed B cells, seemingly unrelated ligands (epitopes) can fit into the pocket formed by the complementarity-determining region (Figure 2Figure 2
Degeneracy of the Antigen Receptor.). Some fit snugly (have high affinity), some loosely (low affinity), and others not at all. The polyspecificity of antigen receptors and the enormous diversity of the randomly assembled repertoire of receptors explain why many B cells and T cells that have not yet encountered a foreign antigen are “anti-self.”15-17 Somatic Mutation of Variable-Region Genes
The role of the B cell is to produce high-affinity protective antibodies. To succeed in this function, it attempts to increase the affinity of its receptors for the immunizing antigen by mutating its variable-region genes.18,19 Mutation of V genes occurs in the germinal center (Figure 3AFigure 3
Lymphocytes.) and requires as yet unknown signals from T cells in the vicinity.20 Virtually all the mutations affect the complementarity-determining regions; successive affinity-increasing mutations force the evolution of clones of B cells that produce high-affinity antibodies. A master gene, activation-induced deaminase, is essential for both somatic mutation of variable-region genes and the switch of the immunoglobulin isotype from IgM to IgG, IgA, or IgE during the immune response.21,22 The variable regions of T cells, by contrast, cannot bind directly to antigen, and their genes do not mutate. Instead, an antigen-activated T cell forms clusters of receptors with high avidity for the immunogen by reorganizing its plasma membrane.23,24 These receptor-rich membrane microdomains most likely account for the clonal selection of antigen-activated T cells.25
How T Cells Recognize Antigens
Dendritic Cells
The long-armed dendritic cell of lymphoid tissue, skin, and squamous epithelium is the antigen-presenting cell par excellence. It engulfs protein antigens, chops them into peptides, and displays the fragments on its surface by means of major-histocompatibility-complex (MHC) molecules (also called HLA molecules).26 The site of engagement between the T cell and the antigen-presenting cell has been termed the immunologic synapse,27 which indeed has some features of the neuronal synapse (Figure 3B).28,29
The MHC Molecule and Self Peptides
Antigen receptors activate the T cell when they bind to the peptide clasped within the groove of an MHC molecule (the antigen receptors of B cells do not require presentation of the antigen by MHC molecules). Some of these peptides originate from microbes, but usually they derive from worn-out nuclear and cytoplasmic proteins.30-32 The MHC molecule, like a garbage truck, carries intracellular junk to the exterior.33,34 The result is that peripatetic T cells constantly encounter a display of potentially immunogenic self peptides on antigen-presenting cells. Yet, in most cases, T cells ignore them and remain quiescent.
Immunoregulation by Positive and Negative Selection of T Cells
T-Cell Differentiation in the Thymus
The T-cell precursor migrates from the bone marrow to the corticomedullary zone of the thymus, where it begins to differentiate, rearrange its variable-region genes, and proliferate. This complex program ends in the medullary region of the thymus, from which the mature T cell exits (Figure 4Figure 4
Differentiation and Selection of T Cells within the Thymus.). In passing through the thymus, more than 98 percent of immature T cells undergo apoptosis. Whether the cell lives or dies depends on the binding affinity of its antigen receptors to peptides within the thymus.35,36 If the binding affinity is high, the cell dies; if there is no affinity, the cell dies. If the affinity is just right, the cell lives. Survival of the developing T cell because of “just-right” affinity is called positive selection; the “wrong” affinity dooms the cell to death by apoptosis (negative selection).37 Ectopic Autoantigens in the Thymus
It is rather amazing that thymic epithelial cells produce and display ectopic autoantigens. Derbinski and colleagues have demonstrated the production by these cells of three islet-cell antigens: glutamic acid decarboxylase (GAD67), insulin, and IA-2.38,39 These thymic cells also produce the type IV collagen autoantigen of Goodpasture's syndrome,40 and it is likely that all the peptides they display derive from autoantigens.41 These self peptides have a central role in orienting the T-cell–receptor repertoire toward self antigens and in eliminating potentially damaging T cells with high affinity to these self antigens.42 The display of autoantigens in the thymus of mice is influenced by the aire gene43; thymic epithelial cells of aire-deficient mice do not display autoantigens.44 Remarkably, a variety of autoimmune diseases develop in humans and mice lacking a functional AIRE or aire gene.45,46
Degeneracy of Antigen Receptors
Not only do most newly minted T cells have anti-self receptors,47 but many B cells emerge from the bone marrow with such receptors.48 However, because of degeneracy in the binding specificities of their receptors, virgin T cells and B cells can also bind foreign antigens.49-51 There is, moreover, clear evidence that mutations in variable-region genes convert these polyspecific anti-self–anti-foreign receptors of B cells into specific anti-foreign receptors.52 The clinical implication here is that immunization can result in the avoidance of autoimmunity, which is a central tenet of the hygiene hypothesis: a “dirty” environment inhibits susceptibility to autoimmune and allergic diseases, whereas a “clean” environment has the opposite effect.53
Activation of Lymphocytes
Activation of mature T cells requires multiple signals.54-57 The binding of the T cell's antigen receptor to an HLA–peptide complex activates only one signal. The others, termed costimulatory signals, are usually a bacterial product like endotoxin, cytokines from activated antigen-presenting cells, or adhesion molecules. Adjuvants in vaccines work by engendering costimulatory signals. Under resting conditions, these signals are switched off, thereby minimizing the risk of autoimmunization. Key costimulatory molecules are members of the B7 family (CD80 and CD86), which are displayed by dendritic cells, and CD28, a glycoprotein on T cells.58 An encounter between B7 and CD28 evokes a signal that helps to activate T cells. If the T cell receives a signal only from its antigen receptor, it enters an unresponsive state called anergy.59-62
Control of T-Cell Activation
CTLA-4
After activation, several mechanisms restore the quiescent state of T cells. An important regulator, CTLA-4 (CD152), appears on activated T cells and blocks the B7–CD28 interaction by competing with CD28 for B7: the affinity of CD80 for CTLA-4 is 20 times as high as its affinity for CD28.63,64 As a result, the T cell returns to a quiescent state. CTLA-4 is a promising target in the treatment of autoimmune diseases and prevention of graft rejection.65,66
Inducible Costimulator
Another regulatory molecule, inducible costimulator, down-regulates pathways that can lead to an autoimmune disease. Inducible costimulator is induced during T-cell activation, and its ligand is a member of the B7 family.67,68 Numerous animal models and studies in humans have demonstrated that if these regulatory molecules or the transcription factors that control them are defective, the result is an autoimmune syndrome with marked lymphoproliferation.69
Regulatory T Cells
More than thirty years ago, Gershon and Kondo described a population of T cells that suppress the immune response of mice to foreign antigens.70 Their report generated considerable excitement, but immunologists lost interest in the phenomenon because of difficulty in reproducing it. Later, it was found that a variety of autoimmune diseases develop in mice whose thymus is removed soon after birth, clearly implying that the thymus produces cells capable of suppressing autoimmunity.71,72
These two phenomena were linked by the discovery of a subpopulation of T cells with CD4 and CD25 surface markers (CD25 is the α chain of the interleukin-2 receptor).73 These T cells have potent inhibitory effects on immune responses to foreign antigens and the development of autoimmunity,74,75 and they can block the development of autoimmune diseases in mice that have undergone thymectomy.76 Within this population of T cells, some members are partially anergic and arise after repeated rounds of antigenic stimulation75; some exert their effects by direct cell-to-cell contact, others by secretion of the cytokine interleukin-10.77,78 These cells turned out to be suppressor T cells; their rediscovery is not just a vindication of Gershon's early work but also a major advance with obvious clinical implications for autoimmunity and transplantation.
The CD2–LFA3 System
After activation by antigen, T cells with low-affinity receptors usually die by apoptosis. By contrast, T cells with high-affinity receptors become memory cells, display CD2, and wander through the skin, lymph nodes, and gut in search of antigen79,80 (Figure 3D). CD2 binds to LFA3, a ligand on dendritic cells.81 The CD2–LFA3 system is a new target of a monoclonal antibody that blocks the interaction between the two molecules as a treatment for psoriasis.82
Rational Medical Control of the Immune System
Immunosuppressive Chemicals
As recently as 1951, the eminent pathologist Arnold Rich was writing about the “mysterious lymphocyte.”83 Even so, there was evidence of the involvement of lymphocytes in immunity, and this led William Dameshek and me to the idea that drugs with activity against lymphocytic leukemia could affect the immune response.84 This hypothesis was supported by the demonstration that the antileukemic compound 6-mercaptopurine suppressed the immune response of rabbits against a foreign protein.85 In lymph nodes draining the site of a skin allograft in a rabbit, numerous primitive lymphocytes (lymphoblasts) were evident five days after placement of the graft (Figure 3C).86 Treatment with 6-mercaptopurine suppressed both the proliferation of lymphoblasts and rejection of the graft.87 These results were quickly confirmed by others with skin grafts in rabbits88 and with canine renal transplants89,90 and then with kidney allografts in humans.91 From these halting steps, which began 40 years ago, organ transplantation has taken major strides. Almost 14,000 renal allografts were transplanted in the United States in 1999.
Dameshek and I found that 6-mercaptopurine and its analogue azathioprine were also effective treatments for corticosteroid-resistant autoimmune hemolytic anemia, systemic lupus erythematosus, and other immunologic diseases.87,92,93 Since then, azathioprine has become widely used in the treatment of a wide variety of immunoinflammatory diseases. The drug is rapidly metabolized to the parent compound, and whether it is genuinely superior to mercaptopurine has not been determined. It is now still used along with many other drugs with immunosuppressive properties that have been introduced into the clinic (Table 1Table 1
Immunosuppressive Drugs in Clinical Use or Clinical Trials.).Monoclonal Antibodies
I can mention here only a few examples of clinically useful monoclonal antibodies. CD52, a small surface protein on T cells and B cells, is the target of Campath-1, a monoclonal antibody with efficacy in the prevention of allograft rejection and the treatment of chronic lymphocytic leukemia94; CD20, found only on B cells, is the target of rituximab, now widely used in the treatment of B-cell lymphomas and certain autoimmune diseases.95 Infliximab, a monoclonal antibody against the inflammatory tumor necrosis factor α (TNF-α), has been found to be effective against rheumatoid arthritis and Crohn's disease.96,97
Monoclonal mouse antibodies that are in clinical use in humans can lead to the formation of antimouse antibodies, which can induce allergic reactions and reduce the effectiveness of the mouse antibody. Steps have been taken to solve this problem by genetic engineering (Figure 5Figure 5
Three Types of Monoclonal Antibodies Now in Clinical Use.). In a chimeric monoclonal antibody, the variable region is of mouse origin and the constant region is of human origin. Such antibodies are less immunogenic than a conventional monoclonal mouse antibody, but they can still evoke neutralizing antibodies and allergic reactions. Infliximab, a chimeric monoclonal antibody against TNF-α, is active against rheumatoid arthritis, Crohn's disease,98 and other immunoinflammatory disorders, but antibodies produced during treatment may be a limiting factor in its long-term usefulness. In a humanized antibody, everything in the molecule is of human origin except the three complementarity-determining regions. Rituximab is such an antibody, and it is readily tolerated and can be given repeatedly.Recombinant Fusion Molecules
A protein consisting of CTLA-4 fused with the constant region of IgG is under active investigation in several autoimmune and inflammatory diseases in which proliferating T cells have been implicated.99 Alefacept is a recombinant fusion protein consisting of LFA3 (the adhesion molecule on antigen-presenting cells that binds to CD2 on memory T cells) and the constant region of IgG. Most lymphocytes in psoriatic lesions have the CD45RO marker of memory T cells and express large amounts of CD2. Alefacept blocks the binding of CD2 to LFA3 and may even kill the T cells in the lesion.82,100 Etanercept consists of the extracellular domain of the tumor-necrosis-factor (TNF) receptor joined to the constant region of IgG. Its main effect is to block the receptor, thereby inhibiting the activity of TNF, a potent activator of inflammation with a key role in rheumatoid arthritis. Etanercept has been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis and is under investigation in juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and a variety of other diseases in which TNF is thought to have a role.101-103
Conclusions
The examples I have selected for discussion show that when basic and clinical sciences are hand-in-hand companions, progress can be extraordinary. We are just beginning to reach the point at which the union of molecular biology, genetic engineering, and genomics will create exceptional opportunities for further advances. It is essential, however, not to allow these dazzling enticements to blind us to our primary goal; our patients must remain the central figures in this endeavor so that progress in immunology leads to true benefit to patients.
Presented as the 112th Shattuck Lecture to the Annual Meeting of the Massachusetts Medical Society, Boston, June 1, 2002.
- References
References
1
Health, United States, 2002: with chartbook on trends in the health of Americans. Washington, D.C.: Government Printing Office, 2002.
2
Ehrlich P . On immunity with special reference to cell life. Proc R Soc Lond 1900;66:424-4483
Cambrosio A ,Jacobi D ,Keating P . Ehrlich's “beautiful pictures“ and the controversial beginnings of immunological imagery. Isis 1993;84:662-699
CrossRef | Web of Science | Medline4
Silverstein AM. Paul Ehrlich's receptor immunology: the magnificent obsession. San Diego, Calif.: Academic Press, 2002.
5
Jerne NK . The natural-selection theory of antibody formation. Proc Natl Acad Sci U S A 1955;41:849-857
CrossRef | Web of Science | Medline6
Burnet FM . A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 1957;20:67-697
Talmage DW . Immunological specificity: unique combinations of selected natural globulins provide an alternative to the classical concept. Science 1959;129:1643-1648
CrossRef | Web of Science | Medline8
Lederberg J . Genes and antibodies. Science 1959;129:1649-1653
CrossRef | Web of Science | Medline9
Schwartz RS . Jumping genes and the immunoglobulin V gene system. N Engl J Med 1995;333:42-44
Full Text | Web of Science | Medline10
Matsuda F ,Honjo T . Organization of the human immunoglobulin heavy-chain locus. Adv Immunol 1996;62:1-29
CrossRef | Web of Science | Medline11
Schwartz RS . Jumping genes. N Engl J Med 1995;332:941-944
Full Text | Web of Science | Medline12
Oettinger MA ,Schatz DG ,Gorka C ,Baltimore D . RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990;248:1517-1523
CrossRef | Web of Science | Medline13
Bassing CH ,Swat W ,Alt FW . The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002;109:Suppl:S45-S55
CrossRef | Web of Science | Medline14
Kabat EA . Origins of antibody complementarity and specificity-hypervariable regions and the minigene hypothesis. J Immunol 1980;125:961-969
Web of Science | Medline15
Schwartz RS ,Stollar BD . Heavy-chain directed B-cell maturation: continuous clonal selection beginning at the pre-B cell stage. Immunol Today 1994;15:27-32
CrossRef | Medline16
Le Campion A ,Bourgeois C ,Lambolez F , et al. Naive T cells proliferate strongly in neonatal mice in response to self-peptide/self-MHC complexes. Proc Natl Acad Sci U S A 2002;99:4538-4543
CrossRef | Web of Science | Medline17
Stefanova I ,Dorfman JR ,Germain RN . Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 2002;420:429-434
CrossRef | Web of Science | Medline18
Stewart AK ,Schwartz RS . Immunoglobulin V regions and the B cell. Blood 1994;83:1717-1730
Web of Science | Medline19
Blanden RV ,Steele EJ . A unifying hypothesis for the molecular mechanism of somatic mutation and gene conversion in rearranged immunoglobulin variable genes. Immunol Cell Biol 1998;76:288-293
CrossRef | Web of Science | Medline20
Kelsoe G . The germinal center: a crucible for lymphocyte selection. Semin Immunol 1996;8:179-184
CrossRef | Medline21
Arakawa H ,Hauschild J ,Buerstedde JM . Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. Science 2002;295:1301-1306
CrossRef | Web of Science | Medline22
Fugmann SD ,Schatz DG . Immunology: one AID to unite them all. Science 2002;295:1244-1245
CrossRef | Web of Science | Medline23
Viola A ,Schroeder S ,Sakakibara Y ,Lanzavecchia A . T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999;283:680-682
CrossRef | Web of Science | Medline24
Monks CR ,Freiberg BA ,Kupfer H ,Sciaky N ,Kupfer A . Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82-86
CrossRef | Web of Science | Medline25
Tuosto L ,Parolini I ,Schroder S ,Sargiacomo M ,Lanzavecchia A ,Viola A . Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001;31:345-349
CrossRef | Web of Science | Medline26
Mellman I ,Steinman RM . Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-258
CrossRef | Web of Science | Medline27
Grakoui A ,Bromley SK ,Sumen C , et al. The immunological synapse: a molecular machine for controlling T cell activation. Science 1999;285:221-227
CrossRef | Web of Science | Medline28
Khan AA ,Bose C ,Yam LS ,Soloski MJ ,Rupp F . Physiological regulation of the immunological synapse by agrin. Science 2001;292:1681-1686
CrossRef | Web of Science | Medline29
Shaw AS ,Allen PM . Kissing cousins: immunological and neurological synapses. Nat Immunol 2001;2:575-576
CrossRef | Web of Science | Medline30
Chicz RM ,Urban RG ,Lane WS , et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992;358:764-768
CrossRef | Web of Science | Medline31
Jardetzky TS ,Lane WS ,Robinson RA ,Madden DR ,Wiley DC . Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-329
CrossRef | Web of Science | Medline32
Kropshofer H ,Max H ,Halder T ,Kalbus M ,Muller CA ,Kalbacher H . Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming. J Immunol 1993;151:4732-4742
Web of Science | Medline33
Klein J ,Sato A . The HLA system. N Engl J Med 2000;343:782-786[Erratum, N Engl J Med 2000;343:1504.]
Full Text | Web of Science | Medline34
Klein J ,Sato A . The HLA system. N Engl J Med 2000;343:702-709
Full Text | Web of Science | Medline35
Anderton SM ,Wraith DC . Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol 2002;2:487-498
CrossRef | Web of Science | Medline36
Anderton SM ,Radu CG ,Lowrey PA ,Ward ES ,Wraith DC . Negative selection during the peripheral immune response to antigen. J Exp Med 2001;193:1-11
CrossRef | Web of Science | Medline37
Margulies DH . TCR avidity: it's not how strong you make it, it's how you make it strong. Nat Immunol 2001;2:669-670
CrossRef | Web of Science | Medline38
Kyewski B ,Derbinski J ,Gotter J ,Klein L . Promiscuous gene expression and central T-cell tolerance: more than meets the eye. Trends Immunol 2002;23:364-371
CrossRef | Web of Science | Medline39
Derbinski J ,Schulte A ,Kyewski B ,Klein L . Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001;2:1032-1039
CrossRef | Web of Science | Medline40
Wong D ,Phelps RG ,Turner AN . The Goodpasture antigen is expressed in the human thymus. Kidney Int 2001;60:1777-1783
CrossRef | Web of Science | Medline41
Ohashi PS . Immunology: exposing thy self. Science 2002;298:1348-1349
CrossRef | Web of Science | Medline42
Nikolic-Zugic J ,Bevan MJ . Role of self-peptides in positively selecting the T-cell repertoire. Nature 1990;344:65-67
CrossRef | Web of Science | Medline43
Zuklys S ,Balciunaite G ,Agarwal A ,Fasler-Kan E ,Palmer E ,Hollander GA . Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Immunol 2000;165:1976-1983
Web of Science | Medline44
Anderson MS ,Venanzi ES ,Klein L , et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298:1395-1401
CrossRef | Web of Science | Medline45
Gibson TJ ,Ramu C ,Gemund C ,Aasland R . The APECED polyglandular autoimmune syndrome protein, AIRE-1, contains the SAND domain and is probably a transcription factor. Trends Biochem Sci 1998;23:242-244
CrossRef | Web of Science | Medline46
Bjorses P ,Aaltonen J ,Horelli-Kuitunen N ,Yaspo ML ,Peltonen L . Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 1998;7:1547-1553
CrossRef | Web of Science | Medline47
Moudgil KD ,Sercarz EE . The self-directed T cell repertoire: its creation and activation. Rev Immunogenet 2000;2:26-37
Medline48
Souroujon M ,White-Scharf ME ,Andre-Schwartz J ,Gefter ML ,Schwartz RS . Preferential autoantibody reactivity of the preimmune B cell repertoire in normal mice. J Immunol 1988;140:4173-4179
Web of Science | Medline49
Dutoit V ,Rubio-Godoy V ,Pittet MJ , et al. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-A peptide multimer(+) CD8(+) T cells in humans. J Exp Med 2002;196:207-216
CrossRef | Web of Science | Medline50
Germain RN . The art of the probable: system control in the adaptive immune system. Science 2001;293:240-245
CrossRef | Web of Science | Medline51
Germain RN ,Stefanova I ,Dorfman J . Self-recognition and the regulation of CD4+ T cell survival. Adv Exp Med Biol 2002;512:97-105
CrossRef | Web of Science | Medline52
Naparstek Y ,Andre-Schwartz J ,Manser T , et al. A single germline VH gene segment of normal A/J mice encodes autoantibodies characteristic of systemic lupus erythematosus. J Exp Med 1986;164:614-626
CrossRef | Web of Science | Medline53
Bach J-F . The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-920
Full Text | Web of Science | Medline54
Bretscher PA ,Cohn M . Minimal model for the mechanism of antibody induction and paralysis by antigen. Nature 1968;220:444-448
CrossRef | Web of Science | Medline55
Abbas AK ,Williams ME ,Burstein HJ ,Chang TL ,Bossu P ,Lichtman AH . Activation and functions of CD4+ T-cell subsets. Immunol Rev 1991;123:5-22
CrossRef | Web of Science | Medline56
Lohoff M ,Koch A ,Rollinghoff M . Two signals are involved in polyclonal B-cell stimulation by T helper type 2 cells: a role for LFA-1 molecules and interleukin 4. Eur J Immunol 1992;22:599-602
CrossRef | Web of Science | Medline57
Bretscher PA . A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 1999;96:185-190
CrossRef | Web of Science | Medline58
Coyle AJ ,Gutierrez-Ramos JC . The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-209
CrossRef | Web of Science | Medline59
Schwartz RH. T cell anergy. Scientific American. August 1993:62-71.
60
Kamradt T ,Mitchison NA . Tolerance and autoimmunity. N Engl J Med 2001;344:655-664
Full Text | Web of Science | Medline61
Quaratino S ,Duddy LP ,Londei M . Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc Natl Acad Sci U S A 2000;97:10911-10916
CrossRef | Web of Science | Medline62
Munder M ,Bettelli E ,Monney L ,Slavik JM ,Nicholson LB ,Kuchroo VK . Reduced self-reactivity of an autoreactive T cell after activation with cross-reactive non-self-ligand. J Exp Med 2002;196:1151-1162
CrossRef | Web of Science | Medline63
Egen JG ,Kuhns MS ,Allison JP . CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618
CrossRef | Web of Science | Medline64
Rudd CE ,Martin M ,Schneider H . CTLA-4 negative signaling via lipid rafts: a new perspective. Sci STKE 2002;2002:PE18-PE18
CrossRef | Medline65
Thompson CB ,Allison JP . The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-450
CrossRef | Web of Science | Medline66
Najafian N ,Sayegh MH . CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs 2000;9:2147-2157
CrossRef | Web of Science | Medline67
Rottman JB ,Smith T ,Tonra JR , et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001;2:605-611
CrossRef | Web of Science | Medline68
Sperling AI ,Bluestone JA . ICOS costimulation: it's not just for TH2 cells anymore. Nat Immunol 2001;2:573-574
CrossRef | Web of Science | Medline69
Bleesing JJ ,Straus SE ,Fleisher TA . Autoimmune lymphoproliferative syndrome: a human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000;47:1291-1310
CrossRef | Web of Science | Medline70
Gershon RK ,Kondo K . Infectious immunological tolerance. Immunology 1971;21:903-914
Web of Science | Medline71
Tung KSK ,Smith S ,Teuscher C ,Cook C ,Anderson RE . Murine autoimmune oophoritis, epididymoorchitis, and gastritis induced by day 3 thymectomy: immunopathology. Am J Pathol 1987;126:293-302
Web of Science | Medline72
Smith H ,Sakamoto Y ,Kasai K ,Tung KSK . Effector and regulatory cells in autoimmune oophoritis elicited by neonatal thymectomy. J Immunol 1991;147:2928-2933
Web of Science | Medline73
Maloy KJ ,Powrie F . Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-822
CrossRef | Web of Science | Medline74
McHugh RS ,Shevach EM ,Thornton AM . Control of organ-specific autoimmunity by immunoregulatory CD4(+)CD25(+) T cells. Microbes Infect 2001;3:919-927
CrossRef | Web of Science | Medline75
Taams LS ,Vukmanovic-Stejic M ,Smith J , et al. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 2002;32:1621-1630
CrossRef | Web of Science | Medline76
Shevach EM . CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400
Web of Science | Medline77
Shevach EM ,McHugh RS ,Piccirillo CA ,Thornton AM . Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001;182:58-67
CrossRef | Web of Science | Medline78
Dieckmann D ,Bruett CH ,Ploettner H ,Lutz MB ,Schuler G . Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002;196:247-253[Erratum, J Exp Med 2002;196:559, 867.]
CrossRef | Web of Science | Medline79
Sasaki T ,Sasaki-Irie J ,Penninger JM . New insights into the transmembrane protein tyrosine phosphatase CD45. Int J Biochem Cell Biol 2001;33:1041-1046
CrossRef | Web of Science | Medline80
Penninger JM ,Irie-Sasaki J ,Sasaki T ,Oliveira-dos-Santos AJ . CD45: new jobs for an old acquaintance. Nat Immunol 2001;2:389-396
Web of Science | Medline81
Sandrin MS ,Mouhtouris E ,Vaughan HA ,Warren HS ,Parish CR . CD48 is a low affinity ligand for human CD2. J Immunol 1993;151:4606-4613
Web of Science | Medline82
Ellis CN ,Krueger GG . Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255
Full Text | Web of Science | Medline83
Silverstein AM . The lymphocyte in immunology: from James B. Murphy to James L. Gowans. Nat Immunol 2001;2:569-571
CrossRef | Web of Science | Medline84
Dameshek W ,Schwartz RS . Leukemia and auto-immunization -- some possible relationships. Blood 1959;14:1151-1158
Web of Science | Medline85
Schwartz R ,Stack J ,Dameshek W . Effect of 6-mercaptopurine on antibody production. Proc Soc Exp Biol Med 1958;99:164-167
Web of Science | Medline86
Andre JA ,Schwartz RS ,Mitus WJ ,Dameshek W . The morphologic responses of the lymphoid system to homografts. I. First and second set responses in normal rabbits. Blood 1962;19:313-348
Web of Science | Medline87
Dameshek W ,Schwartz R . Treatment of certain “autoimmune“ diseases with antimetabolites: a preliminary report. Trans Assoc Am Physicians 1960;73:113-127
Medline88
Meeker W ,Condie R ,Weiner D ,Varco RL ,Good RA . Prolongation of skin homograft survival in rabbits by 6-mercaptopurine. Proc Soc Exp Biol Med 1959;102:459-461
Web of Science89
Calne RY . The rejection of renal homografts: inhibition in dogs by 6-mercaptopurine. Lancet 1960;1:417-418
CrossRef | Web of Science | Medline90
Zukoski CF ,Lee HM ,Hume DM . The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. Surg Forum 1960;11:470-472
Medline91
Murray JE ,Merrill JP ,Harrison JH ,Wilson RE ,Dammin GJ . Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963;268:1315-1323
Full Text | Web of Science | Medline92
Schwartz R ,Dameshek W . The treatment of autoimmune hemolytic anemia with 6-mercaptopurine and thioguanine. Blood 1962;19:483-500
Web of Science | Medline93
Patterson JF ,Norton RA ,Schwartz RS . Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. Am J Dig Dis 1971;16:327-332
CrossRef | Medline94
Dyer MJ . The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:Suppl 14:52-57
Web of Science | Medline95
Johnson PW ,Glennie MJ . Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-1623
CrossRef | Web of Science | Medline96
Lipsky PE ,van der Heijde DMFM ,St Clair EW , et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602
Full Text | Web of Science | Medline97
Present DH ,Rutgeerts P ,Targan S , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405
Full Text | Web of Science | Medline98
Baert F ,Noman M ,Vermeire S , et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2002;348:601-608
Full Text | Web of Science99
Abrams JR ,Lebwohl MG ,Guzzo CA , et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-1252
CrossRef | Web of Science | Medline100
Granstein RD . New treatments for psoriasis. N Engl J Med 2001;345:284-287
Full Text | Web of Science | Medline101
Bathon JM ,Martin RW ,Fleischmann RM , et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593[Erratum, N Engl J Med 2001;344:76, 240.]
Full Text | Web of Science | Medline102
Lovell DJ ,Giannini EH ,Reiff A , et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-769
Full Text | Web of Science | Medline103
Gorman JD ,Sack KE ,Davis JC Jr . Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-1356
Full Text | Web of Science | Medline
- Citing Articles (6)
Citing Articles
1
Gianluigi Mazzoccoli, Lucia Anna Muscarella, Vito Michele Fazio, Ada Piepoli, Valerio Pazienza, Mariangela Pia Dagostino, Francesco Giuliani, Victoria O. Polyakova, Igor Kvetnoy. (2011) Antiphase signalling in the neuroendocrine-immune system in healthy humans. Biomedicine & Pharmacotherapy 65:4, 275-279
CrossRef2
Derek E. Neilson, Mark D. Adams, Caitlin M.D. Orr, Deborah K. Schelling, Robert M. Eiben, Douglas S. Kerr, Jane Anderson, Alexander G. Bassuk, Ann M. Bye, Anne-Marie Childs, Antonia Clarke, Yanick J. Crow, Maja Di Rocco, Christian Dohna-Schwake, Gregor Dueckers, Alfonso E. Fasano, Artemis D. Gika, Dimitris Gionnis, Mark P. Gorman, Padraic J. Grattan-Smith, Annette Hackenberg, Alice Kuster, Markus G. Lentschig, Eduardo Lopez-Laso, Elysa J. Marco, Sotiria Mastroyianni, Julie Perrier, Thomas Schmitt-Mechelke, Serenella Servidei, Angeliki Skardoutsou, Peter Uldall, Marjo S. van der Knaap, Karrie C. Goglin, David L. Tefft, Cristin Aubin, Philip de Jager, David Hafler, Matthew L. Warman. (2009) Infection-Triggered Familial or Recurrent Cases of Acute Necrotizing Encephalopathy Caused by Mutations in a Component of the Nuclear Pore, RANBP2. The American Journal of Human Genetics 84:1, 44-51
CrossRef3
L. Dong, Y. Masaki, T. Takegami, Z.-X. Jin, C.-R. Huang, T. Fukushima, T. Sawaki, T. Kawanami, T. Saeki, K. Kitagawa, S. Sugai, T. Okazaki, Y. Hirose, H. Umehara. (2007) Clonality analysis of lymphoproliferative disorders in patients with Sjögren's syndrome. Clinical & Experimental Immunology 150:2, 279-284
CrossRef4
Gian Franco Gensini, Andrea Alberto Conti, Donatella Lippi. (2007) The contributions of Paul Ehrlich to infectious disease. Journal of Infection 54:3, 221-224
CrossRef5
M. Rodríguez Zapata, M. Álvarez-Mon Soto. (2005) Respuesta inmune frente a la infección. Medicine - Programa de Formación Médica Continuada Acreditado 9:34, 2239-2248
CrossRef6
Ray C.J. Chiu. (2005) “Stealth Immune Tolerance” in Stem Cell Transplantation: Potential for “Universal Donors” in Myocardial Regenerative Therapy. The Journal of Heart and Lung Transplantation 24:5, 511-516
CrossRef
